Roche has signed an exclusive worldwide licence for PTC Therapeutics' spinal muscular atrophy (SMA) programme, which includes three compounds currently in preclinical development, as well as potential back-up compounds. PTC receives $30 million as an upfront payment, up to $460 million in development and commercialisation milestones, and up to double-digit royalties on commercial sales.
PTC's programme has been developed in partnership with the SMA Foundation, which will remain active in the collaboration
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?